Affordable Access

Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer.

Authors
  • Takigawa, N
  • Kiura, K
  • Segawa, Y
  • Watanabe, Y
  • Kamei, H
  • Moritaka, T
  • Shibayama, T
  • Ueoka, H
  • Gemba, K
  • Yonei, T
  • Tabata, M
  • Shinkai, T
  • Hiraki, S
  • Takemoto, M
  • Kanazawa, S
  • Matsuo, K
  • Tanimoto, M
Type
Published Article
Journal
British journal of cancer
Publication Date
Nov 06, 2006
Volume
95
Issue
9
Pages
1142–1144
Identifiers
PMID: 17031394
Source
Medline
License
Unknown

Abstract

Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median follow-up of 8.9 years. The incidence of SPC was 2.4 per 100 patient-years (95% confidence interval: 1.0-4.9).

Report this publication

Statistics

Seen <100 times